Pearce IP BioBlast: w/e 27 Mar 2020

Significant biosimilar activities this week include:

  • At the beginning of March 2020, the UK High Court ruled filing errors in a Supplementary Protection Certificate (SPC) for Lucentis® (ranibizumab) have cut almost two years from Roche/Genentech's protection in the UK. These errors arose when a third party engaged by Roche/Genentech failed to pay the full lump sum fees at the start of the SPC term. 
     

  • On 20 March 2020, Biocon announced it had received an Establishment Inspection Report from the FDA, clearing its manufacturing facility in Bengaluru.
     

  • On 24 March 2020, Alvotech and DKSH announced an exclusive license partnership for the commercialisation of AVT02 (adalimumab candidate) in 36 emerging countries in South-East Asia. Under the agreement, Alvotech will be responsible for development and supply and DKSH will be responsible for registration and commercialisation. 
     

  • On 24 March 2020, Samsung Bioepis announced the FDA has approved its 420mg multi-dose vial of Ontruzant® (trastuzumab).  
     

  • On 26 March 2020, iBio and AzarGen Biotechnologies announced that they have entered into a second Statement of Work under their Master Joint Development Agreement. Under this agreement, iBio will assist AzarGen in the manufacture and characterisation of supplies to enable pre-clinical studies of a rituximab biosimilar.
     

  • On 26 March 2020, Janssen was granted the additional indication of ulcerative colitis for Stelara® (ustekinumab) in Japan.
     

  • On 27 March 2020, Mylan and Lupin announced the EU's CHMP has adopted a positive opinion recommending Nepexto® (etanercept) for all indications as Enbrel®.

Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

November 9, 2020

Please reload

Search by tags